Market closed

Design Therapeutics/$DSGN

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Design Therapeutics

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Ticker

$DSGN
Trading on

Industry

Biotechnology

Employees

54

DSGN Metrics

BasicAdvanced
$391M
Market cap
-
P/E ratio
-$0.85
EPS
1.83
Beta
-
Dividend rate
$391M
1.83
$6.95
$2.25
156K
34.613
34.345
0.691
0.999
-13.54%
-17.78%
1.55
1.55
-8.391
-34.57%
-5.03%

What the Analysts think about DSGN

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Design Therapeutics stock.

DSGN Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

DSGN Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $DSGN

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Design Therapeutics stock?

Design Therapeutics (DSGN) has a market cap of $391M as of December 13, 2024.

What is the P/E ratio for Design Therapeutics stock?

The price to earnings (P/E) ratio for Design Therapeutics (DSGN) stock is 0 as of December 13, 2024.

Does Design Therapeutics stock pay dividends?

No, Design Therapeutics (DSGN) stock does not pay dividends to its shareholders as of December 13, 2024.

When is the next Design Therapeutics dividend payment date?

Design Therapeutics (DSGN) stock does not pay dividends to its shareholders.

What is the beta indicator for Design Therapeutics?

Design Therapeutics (DSGN) has a beta rating of 1.83. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.